viewIntercept Pharmaceuticals

Intercept Pharmaceuticals rises on liver drug approval

Drug company gets accelerated approval for primary biliary cholangitis treatment

Ocaliva is expected to be available to PBC patients in the US within seven to 10 days

Shares in Intercept Pharmaceuticals (NASDAQ: ICPT) got a shot in the arm in pre-open trading on Wall Street after the drug group secured regulatory approval for a liver drug.

The stock bounced US$13.11, or 9.25%, to US$154.88 on news that the FDA had granted accelerated approval to its Ocaliva treatment for primary biliary cholangitis (PBC).

Intercept plans to use Ocaliva, otherwise known as obeticholic acid, in tandem with ursodeoxycholic acid (UDCA) to treat patients who fail to respond to UDCA on its own.

It is expected to be available to PBC patients in the US within seven to 10 days and will be distributed through a specialty pharmacy network.

Chief executive Mark Pruzanski said: “Ocaliva’s approval marks the culmination of more than a decade of work.”

Intercept is hoping for big things from Ocaliva, given that UCDA is the only drug currently approved in the US to treat PBC.

It is also hoping to get it approved in Europe following the European Medicine Authority’s (EMA) acceptance last year of a marketing authorization application.

The EMA is reviewing the application and is due to publish its decision later this year.

There was speculation earlier this year that Intercept’s success with the drug could make it a takeover target.

Quick facts: Intercept Pharmaceuticals

Price: 27.99 USD

Market: NASDAQ
Market Cap: $920.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Namaste releases third quarter financial numbers showing year over year...

Namaste Technologies (CVE: N-OTCMKTS: NXTTF) CEO Meni Morim joined Steve Darling from Proactive to share with viewers the company results from Q-3 2020- Morim noting an improvement in Revenue year over year and a better bottom line. Morim also told Proactive about the real bright spot for the...

27 minutes ago

2 min read